Servier has wrapped up its previously announced acquisition of Symphogen, a Danish antibody discovery company, for an undisclosed price.

The French pharma company signed the deal in April 2020 with a bid to ramp up its antibody capabilities while ensuring that its own antibody discovery and early-development platform is completely leveraged.

Through the acquisition, Servier will get access to Symphogen’s oncology and immune-oncology pipeline programs along with its antibody discovery and development platform.

Claude Bertrand – Executive Vice-President Research & Development at Servier said: “The completion of this acquisition enables Servier to boost its antibody capabilities in oncology and its other therapeutic areas. The efficient antibody discovery and research platform of Symphogen will strengthen our R&D capabilities and pipeline in line with our aim of making life-saving treatments available to more patients across the world.”

The Danish antibody discovery company will now operate as Servier’s antibody center of excellence across various therapeutic areas, including oncology. Symphogen as a Servier subsidiary, will keep its operational autonomy and continue to depend on its employees while retaining its headquarters in Ballerup.

Christophe Thurieau – Executive Director of Servier Research Institute and CEO of Symphogen said: “In line with the values of Symphogen, we also strongly believe that innovation and collaboration are key to develop treatments for the benefit of patients. We are very pleased to welcome Symphogen as part of the Servier Group and look forward to further collaborating with the team on developing breakthrough antibody therapies for patients.”

  Christophe Thurieau, Claude Bertrand, Denmark, France, Pharma acquisition news, Servier, Symphogen